Mellaril is the brand name for thioridazine, an antipsychotic medication used to treat schizophrenia. It is not a first-choice treatment. Due to serious cardiac risks, thioridazine is reserved only for people with schizophrenia who have already tried at least two other antipsychotic medications without adequate results. The Mellaril brand name has been discontinued in the U.S., though generic thioridazine may still be available.
Why Mellaril Is a Last-Resort Medication
Thioridazine carries a black box warning, the most serious safety alert the FDA issues, because it can dangerously disrupt the heart’s electrical rhythm. Specifically, it prolongs a measurement on heart tracings called the QTc interval in a dose-related way. This electrical disruption has been linked to a life-threatening type of irregular heartbeat and sudden death.
Because of this risk, prescribing guidelines are strict: a patient should have tried at least two different antipsychotic drugs, each at an adequate dose and for an adequate duration, before thioridazine is even considered. It exists as an option only when those other medications either didn’t work well enough or caused side effects so severe the person couldn’t continue taking them.
How It Works in the Brain
Thioridazine belongs to an older class of antipsychotics sometimes called “typical” or first-generation antipsychotics. It works primarily by blocking dopamine receptors in the brain. Dopamine is a chemical messenger involved in mood, motivation, and perception. In schizophrenia, overactivity in certain dopamine pathways contributes to symptoms like hallucinations and disordered thinking. By reducing dopamine signaling, thioridazine helps control these symptoms. It also blocks another type of receptor involved in the body’s “fight or flight” response, which accounts for some of its side effects like low blood pressure.
Common Side Effects
Thioridazine’s side effect profile is one reason it fell out of favor as newer antipsychotics became available.
Sexual Dysfunction
This is one of the most frequently reported problems. In studies, roughly 60% of patients experienced some form of sexual dysfunction. Among men specifically, about 44% reported erectile difficulties, often appearing within 24 hours of starting the drug. Women have reported difficulty reaching orgasm. These effects stem from the drug’s interference with nerve signaling in the pelvic area and its strong anticholinergic properties, meaning it blocks a chemical messenger involved in many automatic body functions.
Movement Problems
Like other drugs in its class, thioridazine can cause involuntary movement disorders. These range from muscle stiffness, tremors, and restlessness to a more serious condition called tardive dyskinesia, where a person develops repetitive, uncontrollable movements of the face, tongue, or limbs. Tardive dyskinesia can sometimes persist even after stopping the medication, which is why patients on thioridazine are screened regularly for early signs of abnormal movement.
Eye Damage at High Doses
At doses exceeding 800 mg per day, thioridazine can be toxic to the retina. This damage shows up as pigment changes in the back of the eye and, in severe cases, loss of the cell layers responsible for vision. Patients taking thioridazine typically receive regular eye exams: yearly for those over 40 and every two years for younger patients.
Cardiac Monitoring Requirements
Because of the heart rhythm risks, anyone taking thioridazine needs an electrocardiogram (EKG) before starting the medication. If the heart tracing shows a QTc interval over 500 milliseconds, the drug should be stopped. After the initial EKG, follow-up heart tracings are done 7 to 14 days after any dose change and roughly every six months after that. Blood tests to check potassium and magnesium levels are also part of routine monitoring, since low levels of these minerals make the heart rhythm problem worse.
Thioridazine cannot be combined with other medications that also affect the heart’s electrical timing. Certain antidepressants and antipsychotic combinations are specifically contraindicated. For example, the combination drug containing olanzapine and fluoxetine must not be used with thioridazine, and a five-week washout period is required after stopping that combination before thioridazine can be started.
Other Health Checks During Treatment
Beyond heart monitoring, thioridazine requires a surprisingly long list of ongoing health assessments. Weight and body mass index are tracked monthly for the first six months because antipsychotics can cause significant weight gain. Blood sugar and cholesterol levels are checked about four months after starting the drug and at least once a year thereafter, since antipsychotics raise the risk of metabolic syndrome, a cluster of conditions that includes high blood sugar, excess abdominal fat, and abnormal cholesterol. Complete blood counts and liver function tests round out the routine lab work every six months.
Who Should Not Take It
Thioridazine is not approved for treating behavioral problems in older adults with dementia. People in this group who take antipsychotic medications face an increased risk of death. Beyond dementia, older adults in general are advised against thioridazine because safer alternatives exist. Anyone with a history of heart rhythm disorders, a congenital condition called long QT syndrome, or low potassium or magnesium levels should avoid the drug entirely.
People who process certain medications slowly due to genetic variation in a liver enzyme called CYP2D6, or who take medications that inhibit this enzyme, are also at higher risk. When the body can’t break down thioridazine efficiently, blood levels of the drug rise, amplifying the cardiac danger.